Fundraising FoxELISIGEN
1 known investors
Find your way into ELISIGEN
Sign up to see every warm intro you have to ELISIGEN
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ELISIGEN team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Elisigen develops AAV-based gene therapies designed for durable, long-term therapeutic protein expression in vivo, aiming to reduce repeated dosing. Its pipeline targets conditions including vision loss (such as wet age-related macular degeneration) and chronic pain.
Investors · 1
Frequently asked questions
- What does ELISIGEN do?
- Elisigen develops AAV-based gene therapies designed for durable, long-term therapeutic protein expression in vivo, aiming to reduce repeated dosing. Its pipeline targets conditions including vision loss (such as wet age-related macular degeneration) and chronic pain.
- Who are ELISIGEN's investors?
- ELISIGEN's investors include Premier Partners.